TW202104244A - Fc區域改變抗體的純化方法 - Google Patents

Fc區域改變抗體的純化方法 Download PDF

Info

Publication number
TW202104244A
TW202104244A TW109111941A TW109111941A TW202104244A TW 202104244 A TW202104244 A TW 202104244A TW 109111941 A TW109111941 A TW 109111941A TW 109111941 A TW109111941 A TW 109111941A TW 202104244 A TW202104244 A TW 202104244A
Authority
TW
Taiwan
Prior art keywords
residues
amino acid
antibody
protein
domain
Prior art date
Application number
TW109111941A
Other languages
English (en)
Chinese (zh)
Inventor
若林哲也
清水祐一郎
福永匡宏
真島英司
Original Assignee
日商中外製藥股份有限公司
日商普羅泰納瓦股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商中外製藥股份有限公司, 日商普羅泰納瓦股份有限公司 filed Critical 日商中外製藥股份有限公司
Publication of TW202104244A publication Critical patent/TW202104244A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW109111941A 2019-04-10 2020-04-09 Fc區域改變抗體的純化方法 TW202104244A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019074738 2019-04-10
JP2019-074738 2019-04-10

Publications (1)

Publication Number Publication Date
TW202104244A true TW202104244A (zh) 2021-02-01

Family

ID=72752051

Family Applications (2)

Application Number Title Priority Date Filing Date
TW109111941A TW202104244A (zh) 2019-04-10 2020-04-09 Fc區域改變抗體的純化方法
TW113143764A TW202509054A (zh) 2019-04-10 2020-04-09 Fc區域改變抗體的純化方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW113143764A TW202509054A (zh) 2019-04-10 2020-04-09 Fc區域改變抗體的純化方法

Country Status (13)

Country Link
US (1) US20220213140A1 (https=)
EP (1) EP3954696A4 (https=)
JP (1) JP7583411B2 (https=)
KR (1) KR20210149779A (https=)
CN (1) CN113906042A (https=)
AU (1) AU2020273072B2 (https=)
BR (1) BR112021020204A2 (https=)
CA (1) CA3136398A1 (https=)
IL (1) IL286982A (https=)
MX (1) MX2021012251A (https=)
SG (1) SG11202110986YA (https=)
TW (2) TW202104244A (https=)
WO (1) WO2020209318A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
ES2595638T3 (es) 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
EP2647706B1 (en) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
KR101860280B1 (ko) 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
EP3494991A4 (en) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha COMPOSITION FOR THE PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES
CN115850408A (zh) * 2022-09-01 2023-03-28 西安蓝晓科技新材料股份有限公司 一种多肽、融合型多聚体蛋白质及其用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9022547D0 (en) 1990-10-17 1990-11-28 Wellcome Found Purified immunoglobulin
US5795965A (en) 1991-04-25 1998-08-18 Chugai Seiyaku Kabushiki Kaisha Reshaped human to human interleukin-6 receptor
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
CA2131151A1 (en) 1992-03-24 1994-09-30 Kevin S. Johnson Methods for producing members of specific binding pairs
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
WO1995015388A1 (en) 1993-12-03 1995-06-08 Medical Research Council Recombinant binding proteins and peptides
DE69535243T2 (de) 1994-07-13 2007-05-10 Chugai Seiyaku K.K. Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP2471813B1 (en) 2004-07-15 2014-12-31 Xencor, Inc. Optimized Fc variants
AU2005304624B2 (en) 2004-11-12 2010-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
EP1699826B1 (en) 2005-01-05 2009-03-11 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
JP4179517B2 (ja) * 2006-02-21 2008-11-12 プロテノバ株式会社 イムノグロブリン親和性リガンド
WO2007097361A1 (ja) * 2006-02-21 2007-08-30 Protenova Co., Ltd. イムノグロブリン親和性リガンド
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
KR101680906B1 (ko) 2007-09-26 2016-11-30 추가이 세이야쿠 가부시키가이샤 항체 정상영역 개변체
HRP20150279T1 (hr) 2007-12-26 2015-05-08 Xencor, Inc. Fc inaäśice s promijenjenim vezanjem na fcrn
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
JP5229888B2 (ja) * 2008-09-30 2013-07-03 独立行政法人産業技術総合研究所 弱酸性域での易解離性を向上したプロテインａ変異型タンパク質及び抗体捕捉剤
TWI667257B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
AU2011283694B2 (en) 2010-07-29 2017-04-13 Xencor, Inc. Antibodies with modified isoelectric points
EP2647706B1 (en) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
WO2012132067A1 (ja) 2011-03-30 2012-10-04 中外製薬株式会社 抗原結合分子の血漿中滞留性と免疫原性を改変する方法
EP2690173B1 (en) * 2011-03-25 2019-07-03 Kaneka Corporation Protein for affinity-separation matrix
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
RU2014117505A (ru) 2011-09-30 2015-11-10 Чугаи Сейяку Кабусики Кайся Антигенсвязывающая молекула для ускорения удаления антигенов
EP2857419B1 (en) 2012-05-30 2021-01-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for eliminating aggregated antigens
WO2013180200A1 (ja) 2012-05-30 2013-12-05 中外製薬株式会社 標的組織特異的抗原結合分子
WO2014145159A2 (en) 2013-03-15 2014-09-18 Permeon Biologics, Inc. Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
JP6153801B2 (ja) 2013-07-23 2017-06-28 旭化成ホームズ株式会社 ノズル
JP6456831B2 (ja) * 2013-09-04 2019-01-23 プロテノバ株式会社 イムノグロブリン結合ドメイン多量体
JP2015185254A (ja) 2014-03-20 2015-10-22 日立マクセル株式会社 非水電解質二次電池
KR101860280B1 (ko) * 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
AR107078A1 (es) * 2015-12-18 2018-03-21 Chugai Pharmaceutical Co Ltd Anticuerpo antimiostatina, polipéptidos que contienen regiones fc variantes así como métodos de uso

Also Published As

Publication number Publication date
CA3136398A1 (en) 2020-10-15
BR112021020204A2 (pt) 2021-12-07
JPWO2020209318A1 (https=) 2020-10-15
US20220213140A1 (en) 2022-07-07
WO2020209318A1 (ja) 2020-10-15
MX2021012251A (es) 2021-11-12
TW202509054A (zh) 2025-03-01
EP3954696A1 (en) 2022-02-16
AU2020273072B2 (en) 2026-01-22
AU2020273072A1 (en) 2021-12-09
JP7583411B2 (ja) 2024-11-14
KR20210149779A (ko) 2021-12-09
EP3954696A4 (en) 2023-07-26
CN113906042A (zh) 2022-01-07
IL286982A (en) 2021-12-01
SG11202110986YA (en) 2021-11-29

Similar Documents

Publication Publication Date Title
TW202104244A (zh) Fc區域改變抗體的純化方法
JP7591917B2 (ja) Ｓｉｒｐ－アルファドメインまたはそのバリアントを有する構築物
JP7308892B2 (ja) Ｆｃ領域含有ポリペプチドの精製を効率化するための方法
AU2023204271B2 (en) Method of purifying albumin-fusion proteins
JP2019034963A (ja) 陽イオン交換基を用いた新規抗体精製法（Ｎｏｖｅｌ Ａｎｔｉｂｏｄｙ Ｐｕｒｉｆｉｃａｔｉｏｎ ｍｅｔｈｏｄ ｕｓｉｎｇ Ｃａｔｉｏｎ Ｅｘｃｈａｎｇｅｒ）
CN104640561A (zh) 包含轻链和重链的选择性配对的免疫球蛋白构建体
JP7097293B2 (ja) ヒトＦｃ受容体に結合する融合タンパク質
CN105646643A (zh) 单域抗原结合性分子的纯化方法
CN110312734A (zh) 抗体分离能力改善的Fc结合性蛋白质及使用其的抗体的分离方法
AU2020337333A1 (en) IgM glycovariants
CN106414495A (zh) 抗体处理方法
JP7788379B2 (ja) プロテインａアフィニティークロマトグラフィーを用いた生理活性ペプチドの精製方法
CN111956606A (zh) 包含高浓度抗人白介素23单克隆抗体的低粘度液体制剂
HK40061321A (en) Method for purifying fc region-modified antibody
AU2013381760A1 (en) Purification of proteins using hydrophobic interaction chromatography
CA3231335A1 (en) Bispecific antibody comprising a heterodimer based on mhc proteins
WO2023175064A1 (en) Methods for purifying bispecific antibodies
WO2025250941A1 (en) Cμ4 REGION FOR PAIRING HEAVY AND LIGHT CHAINS IN MULTI-SPECIFIC ANTIBODIES
HK40127110A (zh) 包含人类cd1b(分化簇1)蛋白的异二聚体的抗体样分子
HK40089051A (zh) Egfr结合复合物及其制备和使用方法
HK1251237B (en) Method for promoting efficiency of purification of fc region-containing polypeptide